Last reviewed · How we verify
Avelumab Weekly
Avelumab is a human monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors to reinvigorate anti-tumor immune responses.
Avelumab is a human monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors to reinvigorate anti-tumor immune responses. Used for Metastatic Merkel cell carcinoma, Urothelial carcinoma (bladder cancer), Non-small cell lung cancer.
At a glance
| Generic name | Avelumab Weekly |
|---|---|
| Also known as | Anti-PD-L1, MSB0010718C |
| Sponsor | EMD Serono Research & Development Institute, Inc. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Avelumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the PD-L1/PD-1 and PD-L1/B7.1 inhibitory pathways. This releases the brake on T-cell activation, allowing the immune system to recognize and attack cancer cells more effectively. The weekly dosing schedule is designed to optimize convenience and potentially improve patient compliance compared to standard dosing intervals.
Approved indications
- Metastatic Merkel cell carcinoma
- Urothelial carcinoma (bladder cancer)
- Non-small cell lung cancer
Common side effects
- Fatigue
- Infusion-related reactions
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Immune-mediated colitis
- Hypothyroidism
Key clinical trials
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (PHASE1)
- Trial of INI-4001 in Patients With Advanced Solid Tumours (PHASE1)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (PHASE2)
- Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (PHASE1, PHASE2)
- Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy (NA)
- Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (PHASE3)
- Study of Avelumab-M3814 Combinations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avelumab Weekly CI brief — competitive landscape report
- Avelumab Weekly updates RSS · CI watch RSS
- EMD Serono Research & Development Institute, Inc. portfolio CI